Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub- Analysis of Phase 3 Clinical Trials

키워드

참고문헌 (20)

1. "Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents"[URL]
2. "EACS Guidelines Version 8.0"[URL]
3. Sax PE, "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection:a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks", Lancet, 379, pp.2439~2448 (2012)
4. DeJesus E, "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet, 379, pp.2429~2438 (2012)
5. Zolopa A, "A randomized double-blind comparison of coformulated elvitegravir", cobicistat, tenofovir disoproxil fumarate versus efavirenz, pp.emtricitabine, tenofovir disoproxil fumarate for initial treatment of HIV-1 infection:analysis of week 96 results[DOI]
6. Rockstroh JK, "A randomized, double-blind comparison of co-formulated elvitegravir", cobicistat, tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection:analysis of week 96 results, pp.J Acquir Immune Defic Syndr, 2013[DOI]
7. Rockstroh J, "A randomized, double-blind comparison of coformulated elvitegravir", cobicistat, tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1infection: analysis of week 96 results: erratum, pp.J Acquir Immune Defic Syndr, 2013[DOI]
8. Wohl DA, "A randomized, double-blind comparison of single-tablet regimen elvitegravir", cobicistat, tenofovir DF versus single-tablet regimen efavirenz, pp.emtricitabine, renofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results[DOI]
9. Clumeck N, "A randomized, double-blind comparison of single-tablet regimenelvitegravir", cobicistat, tenofovir DF vs ritonavir-boosted atazanavir plusemtricitabine, pp.tenofovir DF for initial treatment of HIV-1 infection: analysis of week144 results, J Acquir Immune Defic Syndr[DOI]
10. Arribas JR, "Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial", Lancet Infect Dis, 14, pp.581~589 (2014)
11. Pozniak A, "Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial", Lancet Infect Dis, 14, pp.590~599 (2014)
12. "21st Annual Conference of the British HIV Association", 2015, ~
13. "21st Annual Conference of the British HIV Association", 2015, ~
14. Gathe J, "Patient-reported symptoms over 48 weeks in a randomized, open-label, phase 3b noninferiori t y rrial of adults with HIV swi tching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir DF", Patient, 8, pp.445~454 (2015)
15. Mills A, "Patient-reported symptoms over 48 weeks in a randomized, open-label, phase IIIb non-inferiority trial of adults with HIV switching to co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir DF", Patient, 8, pp.359~371 (2015)
16. "Interscience Conference on Infection and Chemotherapy (ICIC)", 2015, ~
17. Cohen C, "Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir", cobicistat, tenofovir disoproxil fumarate versus efavirenz, pp.emtricitabine, tenofovir disoproxil fumarate for the initial treatment of HIV infection[DOI]
18. "51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)", 2011, ~
19. Elion R, "Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixeddose emtricitabine", tenofovir df in the initial treatment of HIV infection, 2011, pp.25, 1881~1886
20. German P, "Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function", J Acquir Immune Defic Syndr, 61, pp.32~40 (2012)

관련 논문AI추천